Pharmafile Logo
Pharmafocus logo
Advanced Search

BioDuro and Atombeat partner to accelerate AI-powered peptide drug discovery

July 31, 2025
Mergers and Acquisitions AI, BioDuro, Corporate, Devices

BioDuro and Atombeat have announced a partnership to launch an artificial intelligence (AI)-driven platform designed to accelerate peptide drug discovery …

News

Key strategies to foster digital transformation in the NHS

July 30, 2025
Business Services, Market Access, Market Access Consultancy Corporate, Gateway to Local Adoption, NHS, Pharmacy, Visions4Health, digital transformation, pharmacy

In the third of the Gateway to Local Adoption series, Visions4Health caught up with James Scott, Digital and Informatics Specialist …

Feature

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

July 30, 2025
Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …

News
laboratory-testing-az

Clinisys acquires Orchard Software to expand laboratory informatics leadership

July 30, 2025
Analytical & Laboratory Services, Mergers and Acquisitions, Research and Development Clinisys, Corporate, Francisco Partners, Orchard Software, laboratory informatics, laboratory information management systems

Clinisys has announced the acquisition of Orchard Software from Francisco Partners, strengthening its position in laboratory informatics. The strategic acquisition …

News
alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

July 30, 2025
Research and Development Alzheimer's disease, CE Mark approval, Eli Lilly, Neurology, Roche

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in vitro diagnostic regulation-certified blood-based diagnostic …

News
europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025
Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …

News

ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development

July 29, 2025
Contract Manufacturing, Manufacturing Services, Mergers and Acquisitions, Research and Development AvenCell Therapeutics, CAR-T therapy, Contract Development Manufacturing Organisation, Good Manufacturing Practice, Immunology, Oncology, ViroCell Biologics, autoimmune diseases, blood cancer

ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical …

News

Relief Therapeutics to merge with NeuroX to create AI-driven neurohealth company

July 29, 2025
Mergers and Acquisitions, Research and Development AI, Corporate, MindMaze, Neurology, Relief Therapeutics, neurological conditions

Relief Therapeutics has announced that it will combine with NeuroX Group, the successor to digital neurotherapeutics company MindMaze. The transaction …

News

Universal Quantum partners with Open Quantum Institute to tackle endometriosis with new technology

July 29, 2025
Medical Communications, Research and Development Open Quantum Institute, Pain, Reproductive health, UN Sustainable Development Goals, United Nations, Universal Quantum, endometriosis, women's health

Based in Brighton, UK, Universal Quantum has joined the Open Quantum Institute (OQI) to explore how quantum computing could revolutionise …

News
Prescriptions image

Mental health medicine use in England reaches record high, NHSBSA report reveals

July 29, 2025
Manufacturing and Production, Medical Communications, Research and Development ADHD, COVID-19, NHS Business Services Authority, Psychiatry, antidepressants, antipsychotics, anxiolytics, barbiturate, dementia, hypnotics, mental health

According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions in England have reached their …

News

Bristol Myers Squibb appoints Cristian Massacesi as chief medical officer and head of development

July 28, 2025
Research and Development Bristol Myer Squibb, Corporate, Executive Leadership Team, Head of Development, chief medical officer, executive vice president

Bristol Myers Squibb (BMS) has announced the appointment of Cristian Massacesi as executive vice president, chief medical officer, and head …

Appointment

Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate

July 28, 2025
Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis

Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …

Appointment
mental-health-3332122_960_720

Seaport Therapeutics doses first patient in trial of GlyphAllo for depression

July 25, 2025
Research and Development Psychiatry, Seaport Therapeutics, clinical trial, major depressive disorder, mental health, neuropsychiatric conditions

Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …

News

Cube Biotech appoints Michael Bencak as new CEO amid global expansion plans

July 25, 2025
Mergers and Acquisitions, Research and Development CEO, Corporate, Cube Biotech, IBA Lifescience, archimed, executive chairman

Cube Biotech has announced a leadership transition as the company continues its trajectory of global growth and innovation in protein …

Appointment

PureTech Health appoints interim CEO Robert Lyne

July 24, 2025
Research and Development Corporate, PureTech Health, board of directors, chief portfolio officer, interim CEO

PureTech Health has announced the departure of chief executive officer (CEO) Bharatt Chowrira, who has stepped down from his role …

Appointment
eyeimagenotext-1

OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain

July 24, 2025
Research and Development OKYO Pharma, Opthalmology, clinical trial, neuropathic corneal pain, ocular pain

OKYO Pharma has announced positive results from its phase 2 trial of urcosimod (formerly OK-101) in neuropathic corneal pain (NCP), …

News

Yourgene Health launches LightBench Discover for long-read sequencing labs

July 23, 2025
Business Services, Technical Consultancy Devices, Novacyt, PacBio, Yourgene Health, molecular diagnostics

Yourgene Health, part of the Novacyt group, has announced the launch of LightBench Discover, an integrated benchtop instrument designed to …

News
handshake-1910702_960_720

Evestia Clinical and Atlantic Research Group merge to create global specialist CRO

July 23, 2025
Clinical Trial Services, Mergers and Acquisitions, Research and Development Atlantic Research Group, Corporate, Evestia Clinical, clinical trials, contract research organisation

UK-based Evestia Clinical will merge with US-based Atlantic Research Group (ARG), forming a leading independent global contract research organisation (CRO) …

News

MetP Pharma releases positive data on intranasal semaglutide administration

July 22, 2025
Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide

MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …

News

Takara and Macherey-Nagel enter distribution agreement for global expansion

July 22, 2025
Mergers and Acquisitions Devices, Macherey-Nagel, Microbiology, Takara, Takara Bio Europe

Takara Bio Europe has entered into a distribution agreement with Macherey-Nagel (MN), an analytical and bioanalytical product provider, to expand …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026